2013 ACR/ARHP Annual Meeting

October 25-30, 2013. San Diego, CA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2726

A Polymorphism In The Mif Gene Is Associated With Cardiovascular Morbidity In Systemic Lupus Erythematosus – a Pilot Study
Abstract Number: 137

A Population-Based Survey and Physician Assessment Of The Characteristics and Prevalence Of Fibromyalgia
Abstract Number: 648

A Possible Contribution of Inducible Costimulator to the Development of Skin Sclerosis and Interstitial Lung Disease in Systemic Sclerosis
Abstract Number: 1167

A Possible Mechanism Of NLRP3 Inflammasome Hypersensitivity In Cryopyrin-Associated Periodic Syndrome
Abstract Number: 1097

A Potential Use Of Neurotropin^TM, a Novel Neuro-Modulating Medication, For The Treatment Of Chronic Pain and Fibromyalgia
Abstract Number: 1721

A Prediction Tool for Incident Gout Among Those With Hyperuricemia
Abstract Number: 1201

A Progress Report On An Emerging Disease: NOD2-Associated Autoinflammatory Disease
Abstract Number: 1116

A Prospective Evaluation Of The Diagnostic Value Of Conventional Radiography, Ultrasound and MRI In Comparison To Clinical Examination For The Assessment Of Heel and Knee Enthesitis In Patients With Peripheral Spondyloarthritis and Controls
Abstract Number: 1242

A Prospective Randomized Open Label Trial To Evaluate The Effect Of Food On Vitamin D Absorption
Abstract Number: 903

A Qualitative Study Of The Educational Needs Of Children With Scleroderma and Their Parents
Abstract Number: 2848

A Randomised Controlled Trial (RCT) of Telephone Delivered Cognitive Behaviour Therapy (tCBT) and Exercise In The Management Of Chronic Widespread Pain (CWP): Identifying Long-Term Outcome and Who Benefits From Which Treatment
Abstract Number: 1694

A Randomised Trial Of A Brace For Patellofemoral Osteoarthritis Targeting Knee Pain and Bone Marrow Lesions
Abstract Number: 1779

A Randomized Controlled, Clinical, Histological and mRNA Profiling Pilot Study Of Endurance Exercise In Myositis
Abstract Number: 501

A Randomized Placebo-Controlled Phase 2 Study To Evaluate Efficacy, Safety and Tolerability Of Two Secukinumab Loading Dose Regimens In Subjects With Active Rheumatoid Arthritis Despite Treatment With Methotrexate
Abstract Number: 1107

A Randomized Trial Of a Physical Self-Management Program For Fibromyalgia Syndrome

« Previous Page
1
…
3
4
5
6
7
…
193
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].